心血管疾病使用沙库巴曲缬沙坦治疗的研究进展

摘要/Abstract

摘要： 沙库巴曲缬沙坦是一种新型的心力衰竭治疗药物,通过抑制脑钠肽酶和拮抗血管紧张素II受体,发挥降压作用,改善心肌收缩功能。沙库巴曲缬沙坦可显著降低心衰患者的全因死亡率,此外,沙库巴曲缬沙坦还展现出抗炎、抗心律失常及改善心室重塑方面的潜力,为心血管疾病的综合管理提供了新的治疗思路。但应用沙库巴曲缬沙坦在某些患者中仍可能出现肾功能不全和低血压等不良反应,因此,临床应用时需谨慎评估患者的个体情况。本文综述了沙库巴曲缬沙坦在心血管疾病治疗中的最新研究进展,探讨其作用机制、临床效果及安全性,以期为临床实践提供参考。

关键词: 沙库巴曲缬沙坦, 心力衰竭, 高血压, 心律失常

赵婷婷, 张凡, 陈舒莟. 心血管疾病使用沙库巴曲缬沙坦治疗的研究进展[J]. 心血管病防治知识, 2025, 15(8): 142-144.

参考文献

[1] Chong B, Jayabaskaran J, Jauhari SM, et al.Global burden of cardiovascular diseases: projections from 2025 to 2050[J]. Eur J Prev Cardiol, 2024, zwae281.
[2] McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)[J]. Eur J Heart Fail, 2014, 16(7): 817-825.
[3] Tokudome T, Otani K.Molecular Mechanism of Blood Pressure Regulation through the Atrial Natriuretic Peptide[J]. Biology (Basel), 2022, 11(9): 1351.
[4] Sarzani R, Allevi M, Di Pentima C, et al.Role of cardiac natriuretic peptides in heart structure and function[J]. Int J Mol Sci, 2022, 23(22): 14415.
[5] Saravi B, Li Z, Lang CN, et al.The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?[J]. Cells, 2021, 10(3): 650.
[6] Vitiello A, La Porta R, Trama U, Troiano V, Ferrara F.Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia[J]. Inflammopharmacology, 2022, 30(4): 1407-1410.
[7] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(48): 4901.
[8] Girerd N, Cleland J, Anker SD, et al.Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction[J]. Sci Rep, 2022, 12(1): 8574.
[9] Pontremoli R, Borghi C, Perrone Filardi P.Renal protection in chronic heart failure: focus on sacubitril/valsartan[J]. Eur Heart J Cardiovasc Pharmacother, 2021, 7(5): 445-452.
[10] Bunsawat K, Ratchford SM, Alpenglow JK, et al.Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction[J]. J Appl Physiol (1985), 2021, 130(1): 256-268.
[11] Bolla GB, Fedele A, Faggiano A, et al.Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction[J]. BMC Cardiovasc Disord, 2022, 22(1): 217.
[12] Qiao Y, Shin JI, Chen TK, et al.Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate[J]. JAMA Intern Med, 2020, 180(5): 718-726.
[13] Fu EL, Evans M, Clase CM, et al.Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study[J]. J Am Soc Nephrol, 2021, 32(2): 424-435.
[14] Chrysanthopoulou A, Gkaliagkousi E, Lazaridis A, et al.Angiotensin II triggers release of neutrophil extracellular traps, linking thromboinflammation with essential hypertension[J]. JCI Insight, 2021, 6(18): e148668.
[15] Honda A, Tahara N, Tahara A, et al.Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation[J]. J Nucl Cardiol, 2023, 30(4): 1613-1626.
[16] Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J.Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study[J]. Hypertens Res, 2022, 45(5): 824-833.
[17] Jackson AM, Jhund PS, Anand IS, et al.Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J]. Eur Heart J, 2021, 42(36): 3741-3752.
[18] Liu X, Liu H, Wang L, et al.Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials[J]. PLoS One, 2022, 17(1): e0263131.
[19] Sutanto H, Lyon A, Lumens J, et al.Cardiomyocyte calcium handling in health and disease: Insights from in vitro and in silico studies[J]. Prog Biophys Mol Biol, 2020, 157: 54-75.
[20] Eiringhaus J, Wünsche CM, Tirilomis P, et al.Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca²+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure[J]. ESC Heart Fail, 2020, 7(5): 2992-3002.
[21] Belarte-Tornero LC, Mojón D, Solé-González E, et al.Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction[J]. Rev Esp Cardiol (Engl Ed), 2021, 74(12): 1117-1119.
[22] Huo JY, Jiang WY, Chen C, et al.Effects of angiotensin receptor neprilysin inhibitors on inducibility of ventricular arrhythmias in rats with ischemic cardiomyopathy[J]. Int Heart J, 2019, 60(5): 1168-1175.